419 related articles for article (PubMed ID: 16210034)
1. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
2. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
3. A novel thrombopoietin signaling defect in polycythemia vera platelets.
Moliterno AR; Siebel KE; Sun AY; Hankins WD; Spivak JL
Stem Cells; 1998; 16 Suppl 2():185-92. PubMed ID: 11012190
[TBL] [Abstract][Full Text] [Related]
4. In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders.
Weinberg RS
Semin Hematol; 1997 Jan; 34(1):64-9. PubMed ID: 9025164
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloproliferative disorders.
Spivak JL; Barosi G; Tognoni G; Barbui T; Finazzi G; Marchioli R; Marchetti M
Hematology Am Soc Hematol Educ Program; 2003; ():200-24. PubMed ID: 14633783
[TBL] [Abstract][Full Text] [Related]
6. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
Tefferi A
Mayo Clin Proc; 1998 Dec; 73(12):1177-84. PubMed ID: 9868417
[TBL] [Abstract][Full Text] [Related]
7. Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche.
Flosdorf N; Böhnke J; de Toledo MAS; Lutterbach N; Lerma VG; Graßhoff M; Olschok K; Gupta S; Tharmapalan V; Schmitz S; Götz K; Schüler HM; Maurer A; Sontag S; Küstermann C; Seré K; Wagner W; Costa IG; Brümmendorf TH; Koschmieder S; Chatain N; Castilho M; Schneider RK; Zenke M
Stem Cell Reports; 2024 Feb; 19(2):224-238. PubMed ID: 38278152
[TBL] [Abstract][Full Text] [Related]
8. JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management.
Gangat N; Szuber N; Tefferi A
Am J Hematol; 2023 Jun; 98(6):965-981. PubMed ID: 36966432
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of polycythemia vera.
Fernandez-Luna JL; Silva M; Richard C; Sanz C; Benito A
Haematologica; 1998 Feb; 83(2):150-8. PubMed ID: 9549927
[TBL] [Abstract][Full Text] [Related]
10. Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency.
Aladağ E; Aksu S; Demiroğlu H; Sayınalp N; Göker H; Haznedaroğlu İC; Özcebe Oİ; Büyükaşık Y
Turk J Med Sci; 2019 Oct; 49(5):1560-1563. PubMed ID: 31652037
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
Li Z; Xu M; Xing S; Ho WT; Ishii T; Li Q; Fu X; Zhao ZJ
J Biol Chem; 2007 Feb; 282(6):3428-32. PubMed ID: 17178722
[TBL] [Abstract][Full Text] [Related]
12. Comparison of erythroid progenitor cell growth in vitro in polycythemia vera and chronic myelogenous leukemia: only polycythemia vera has endogenous colonies.
Weinberg RS; Worsley A; Gilbert HS; Cuttner J; Berk PD; Alter BP
Leuk Res; 1989; 13(4):331-8. PubMed ID: 2716348
[TBL] [Abstract][Full Text] [Related]
13. Identification of an acquired JAK2 mutation in polycythemia vera.
Zhao R; Xing S; Li Z; Fu X; Li Q; Krantz SB; Zhao ZJ
J Biol Chem; 2005 Jun; 280(24):22788-92. PubMed ID: 15863514
[TBL] [Abstract][Full Text] [Related]
14. Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies.
Le Couedic JP; Mitjavila MT; Villeval JL; Feger F; Gobert S; Mayeux P; Casadevall N; Vainchenker W
Blood; 1996 Feb; 87(4):1502-11. PubMed ID: 8608241
[TBL] [Abstract][Full Text] [Related]
15. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin.
Liu E; Jelinek J; Pastore YD; Guan Y; Prchal JF; Prchal JT
Blood; 2003 Apr; 101(8):3294-301. PubMed ID: 12515724
[TBL] [Abstract][Full Text] [Related]
16. JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
Patel AB; Franzini A; Leroy E; Kim SJ; Pomicter AD; Genet L; Xiao M; Yan D; Ahmann JM; Agarwal AM; Clair P; Addada J; Lambert J; Salmon M; Gleich GJ; Cross NCP; Constantinescu SN; O'Hare T; Prchal JT; Deininger MW
Blood; 2019 Dec; 134(26):2388-2398. PubMed ID: 31697804
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and laboratory features compared between JAK2 exon12 and JAK2 V617F mutated polycythemia vera].
Liu D; Zhang PH; Xu ZF; Ma J; Qin TJ; Qu SQ; Sun XJ; Li B; Pan LJ; Jia YJ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):107-114. PubMed ID: 35381670
[No Abstract] [Full Text] [Related]
18. Altered Ca
Buks R; Dagher T; Rotordam MG; Monedero Alonso D; Cochet S; Gautier EF; Chafey P; Cassinat B; Kiladjian JJ; Becker N; Plo I; Egée S; El Nemer W
Cells; 2021 Dec; 11(1):. PubMed ID: 35011611
[TBL] [Abstract][Full Text] [Related]
19. Endogenous erythroid and megakaryocytic colony formation in serum-free, cytokine-free collagen gels.
Dobo I; Pineau D; Zandecki M; Hunault M; Hermouet S
J Hematother Stem Cell Res; 1999 Dec; 8(6):601-7. PubMed ID: 10645767
[TBL] [Abstract][Full Text] [Related]
20. [Effect of bloodletting on the proliferative activity of erythroid progenitor cells from the bone marrow of patients with polycythemia and polycythemia vera].
Hansz J; Kozłowska-Skrzypczak M
Pol Arch Med Wewn; 1991 Sep; 86(3):125-31. PubMed ID: 1808597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
